m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00016)
Regulator Name Methyltransferase-like 13 (METTL13)
Synonyms
eEF1A-KNMT; eEF1A lysine and N-terminal methyltransferase; EEF1AKNMT; FEAT; KIAA0859; CGI-01
    Click to Show/Hide
Gene Name METTL13
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
PI3-kinase beta (PIK3CB)
Buparlisib [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for Buparlisib. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
PA-799 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for PA-799. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [3]
PQR309 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for PQR309. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of PQR309 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [4]
AZD8186 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for AZD8186. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of AZD8186 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [5]
BAY 1082439 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [6]
GSK2636771 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for GSK2636771. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of GSK2636771 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [7]
3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). [1], [8]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of PI3-kinase beta (PIK3CB). [1], [9]
ISIS 31963 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31963. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 31963 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 31982 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31982. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 31982 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 31996 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31996. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 31996 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32000 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32000. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32000 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32002 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32002. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32002 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32003 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32003. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32003 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32004 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32004. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32004 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32005 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32005. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32005 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32006 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32006. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32006 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32008 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32008. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32008 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32010 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32010. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32010 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32014 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32014. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32014 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32015 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32015. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32015 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32020 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32020. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32020 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32021 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32021. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32021 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32024 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32024. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32024 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32028 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32028. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32028 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32035 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32035. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32035 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [10]
ISIS 32039 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32039. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of ISIS 32039 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [11]
KU-0060648 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for KU-0060648. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of KU-0060648 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [12]
LY-292223 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [11]
PI-3065 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for PI-3065. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of PI-3065 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [9]
PIK-75 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for PIK-75. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of PIK-75 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [13]
PP121 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for PP121. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of PP121 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [14]
TGX-221 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [15]
References
Ref 1 N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020 Dec;69(12):2180-2192. doi: 10.1136/gutjnl-2019-320179. Epub 2020 Apr 20.
Ref 2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 3 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401. doi: 10.1021/jm400915j. Epub 2013 Aug 1.
Ref 4 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
Ref 6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).
Ref 7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 8 Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54. doi: 10.1016/j.ejca.2009.03.002. Epub 2009 Apr 1.
Ref 9 Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. doi: 10.1016/j.bmc.2007.05.070. Epub 2007 Jun 6.
Ref 10 US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
Ref 11 LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. doi: 10.1016/s0960-894x(01)00099-3.
Ref 12 PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14. doi: 10.1038/nm1232. Epub 2005 Apr 17.
Ref 13 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. doi: 10.1038/nchembio.117. Epub 2008 Oct 12.
Ref 14 Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36.
Ref 15 Inactivation of PI(3)K p110Delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.